ImmunityBio, Inc.
IBRX
Pozycja w akcjach
#2232
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and... ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
Cena akcji
$8.55
Ostatnia synchronizacja: 2026-10-19
Kapitalizacja rynkowa
$9.06B
Zmiana (1 dzień)
-6.84%
Zmiana (1 rok)
249.08%
Kraj
US
Handel ImmunityBio, Inc. (IBRX)
Kategoria
Healthcare
Liczba akcji w obrocie dla ImmunityBio, Inc. (IBRX)
Liczba akcji w obrocie na dzień June 2026: 1.05B
Zgodnie z najnowszymi raportami finansowymi i ceną akcji ImmunityBio, Inc., aktualna liczba akcji w obrocie to 1.05B. Na koniec December 2023 firma posiadała 508.64M akcji w obrocie. Liczba akcji w obrocie jest zwykle kształtowana przez podziały akcji i skupy akcji.
Historia liczby akcji w obrocie dla ImmunityBio, Inc. (IBRX) od 2013 do 2026
Akcje w obrocie na koniec każdego roku
| Rok | Akcje w obrocie | Zmień |
|---|---|---|
| 2026 (TTM) | 1.05B | 50.59% |
| 2024 | 697.31M | 37.09% |
| 2023 | 508.64M | 27.19% |
| 2022 | 399.90M | 2.74% |
| 2021 | 389.23M | 1.58% |
| 2020 | 383.18M | 0.00% |
| 2019 | 383.18M | 17.88% |
| 2018 | 325.05M | 2.81% |
| 2017 | 316.15M | -3.78% |
| 2016 | 328.55M | 0.69% |
| 2015 | 326.30M | 3.35% |
| 2014 | 315.73M | 0.00% |
| 2013 | 315.73M | 0.00% |
Akcje w obrocie dla podobnych firm lub konkurentów
| Firma | Akcje w obrocie | Różnica | Kraj |
|---|---|---|---|
| 253.90M | -75.82% |
US
|
|
| 396.00M | -62.29% |
US
|
|
| 478.91M | -54.39% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -94.08% |
NL
|
